Uniden­ti­fied wit­ness­es ac­cuse Bris­tol My­ers of scut­tling time­ly FDA move on liso-cel to avoid $6.4B pay­out

Back in June, dis­grun­tled Cel­gene share­hold­ers filed a law­suit against Bris­tol My­ers Squibb, ac­cus­ing the phar­ma gi­ant of pur­pose­ly slow-rolling Breyanzi’s ap­proval to avoid mak­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER